Drug Profile


Alternative Names: (-)-MSP-2017; MSP-2017; MSP-2017A; MSP-2017B

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Milestone Pharmaceuticals
  • Class Antiarrhythmics; Benzoates; Esters; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal supraventricular tachycardia
  • Preclinical Angina pectoris

Most Recent Events

  • 11 May 2017 Efficacy and safety data from the phase II NODE-1 trial in Paroxysmal supraventricular tachycardia released by Milestone Pharmaceuticals
  • 11 May 2017 Milestone Pharmaceuticals plans a phase III trial for Paroxysmal supraventricular tachycardia
  • 11 May 2017 Milestone Pharmaceuticals plans a phase III trial in patients with atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular re-entry tachycardia (AVRT)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top